ZYME
Biotechnology · Healthcare
Head of Investor Relations
Head of Investor Relations
Jazz Pharmaceuticals plc (JAZZ)Head of Investor Relations
Zymeworks Inc. (ZYME)Equibles does not estimate personal net worth.
Get an email with a short summary when Jazz Pharmaceuticals plc publishes a filing, an earnings call transcript or a press release.
Get JAZZ alertsJack Spinks is recorded as Head of Investor Relations at Jazz Pharmaceuticals plc (JAZZ) and Head of Investor Relations at Zymeworks Inc. (ZYME). Jack Spinks has spoken on 6 earnings calls and 1 other investor event across 2 companies, most recently for Jazz Pharmaceuticals plc on May 19, 2026. Those appearances were for Zymeworks Inc. (ZYME) and Jazz Pharmaceuticals plc (JAZZ). Zymeworks Inc. is classified in the Biotechnology industry within the Healthcare sector. Jazz Pharmaceuticals plc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Zymeworks Inc. includes Ali Tehrani (CEO), Kenneth Galbraith (CEO and CFO), Kristin Stafford (CFO) and 7 others.
“And I think commercially, Leo, you know, we're really happy that we have the triplet OS, which was positive, you know, in the data readout in earlier this year.”
“Today, Jazz Pharmaceuticals reported its third quarter 2025 financial results. The slide presentation accompanying this webcast is available on the Investors section of our website.”
“Today we will discuss our first quarter financial results, as well as provide an update to our ongoing business.”
“Today, we will discuss our fourth quarter and full year 2022 financial results, as well as provide an update to our ongoing business.”
“Today, we will discuss our third quarter 2022 financial results, as well as provide an update on our ongoing business.”
ZYME
Biotechnology · Healthcare
Head of Investor Relations
Biotechnology · Healthcare
Head of Investor Relations